Impact of Different Factors on the Probability of Clinical Response in Tigecycline-Treated Patients with Intra-Abdominal Infections

被引:14
作者
Bhavnani, S. M. [1 ]
Rubino, C. M. [1 ]
Ambrose, P. G. [1 ]
Babinchak, T. J. [2 ]
Korth-Bradley, J. M. [2 ]
Drusano, G. L. [3 ]
机构
[1] Ordway Res Inst, Inst Clin Pharmacodynam, Latham, NY 12110 USA
[2] Wyeth Pharmaceut, Collegeville, NY USA
[3] Ordway Res Inst, Albany, NY USA
关键词
PERFORATED APPENDICITIS; PERITONITIS; PROGNOSIS; STRATIFICATION; MANAGEMENT; EFFICACY; TRIALS;
D O I
10.1128/AAC.00182-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Patients with intra-abdominal infections differ with regard to the type of infection and the severity of illness. However, the impact of these factors, together with differences in drug exposure, on clinical response is not well understood. Using phase 2 and 3 data for patients with complicated intra-abdominal infections, the relative importance of tigecycline exposure, host factors, and disease factors, alone or in combination, for the probability of clinical response was examined. Patients with complicated intra-abdominal infections who received tigecycline intravenously as a 100-mg loading dose followed by 50 mg every 12 h for 5 to 14 days and who had adequate clinical, pharmacokinetic, and response data were evaluated. Multivariable logistic regression was used to identify factors associated with clinical response. A final multivariable logistic regression model demonstrated six factors based on 123 patients to be predictive of clinical success: a weight of < 94 kg (P = 0.026), the absence of Pseudomonas aeruginosa in baseline cultures (P = 0.021), an APACHE II score of < 13 (P = 0.029), non-Hispanic race (P = 0.005), complicated appendicitis or cholecystitis (P = 0.004), and a ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio) of >= 3.1 (P = 0.003). The average model-predicted probability of clinical success when one unfavorable factor was present was 0.940. This probability was lower (0.855) when the AUC/MIC ratio was < 3.1 and the remaining five factors were set to the favorable condition. The average model-predicted probability of clinical success in the presence of two unfavorable factors was 0.594. These findings demonstrated the impact of individual and multiple factors on clinical response in the context of drug exposure.
引用
收藏
页码:1207 / 1212
页数:6
相关论文
共 29 条
[1]   The bacterial flora of acute perforated appendicitis with peritonitis - A bacteriologic study based upon one hundred cases [J].
Altemeier, WA .
ANNALS OF SURGERY, 1938, 107 :517-528
[2]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[3]   Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints [J].
Ambrose, Paul G. ;
Meagher, Alison K. ;
Passarell, Julie A. ;
Van Wart, Scott A. ;
Cirincione, Brenda B. ;
Rubino, Chris M. ;
Korth-Bradley, Joan M. ;
Babinchak, Timothy ;
Ellis-Grosse, Evelyn .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (01) :38-42
[4]   The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].
Babinchak, T ;
Ellis-Grosse, E ;
Dartois, N ;
Rose, GM ;
Loh, E .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367
[5]   Impact of obesity on surgical outcomes after colorectal resection [J].
Benoist, S ;
Panis, Y ;
Alves, A ;
Valleur, P .
AMERICAN JOURNAL OF SURGERY, 2000, 179 (04) :275-281
[6]   ANTIBIOTIC MANAGEMENT OF SURGICALLY TREATED GANGRENOUS OR PERFORATED APPENDICITIS - COMPARISON OF GENTAMICIN AND CLINDAMYCIN VERSUS CEFAMANDOLE VERSUS CEFOPERAZONE [J].
BERNE, TV ;
YELLIN, AW ;
APPLEMAN, MD ;
HESELTINE, PNR .
AMERICAN JOURNAL OF SURGERY, 1982, 144 (01) :8-13
[7]  
BOHNEN J, 1983, ARCH SURG-CHICAGO, V118, P285
[8]   In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections [J].
Bradford, PA ;
Weaver-Sands, DT ;
Petersen, PJ .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S315-S332
[9]  
CHRISTOU NV, 1993, ARCH SURG-CHICAGO, V128, P193
[10]  
Clinical and Laboratory Standards Institute, 2005, M100S15 CLSI